NEW YORK – Cancer diagnostics company Interpace Biosciences said on Wednesday that it is teaming up with Miroculus and Twist Bioscience to automate next-generation sequencing library preparation using digital microfluidics technology for cancer testing.
Through the collaboration, Interpace Biosciences’ clinical services branch, Interpace Diagnostics, will integrate Twist’s library prep and hybridization capture chemistries with Miroculus’ digital microfluidics instrument, the Miro Canvas, to automate Interpace’s custom NGS panels. This will enable low volume, accurate, and precise sample preparation for genetic testing of endocrine and GI cancers, the company said.
The effort will help minimize hands-on technician time and accelerate the implementation of diagnostic testing and assessment for cancer patients, according to Interpace.
“Our goal is to transform our CLIA laboratory into a high-throughput, state-of-the-art automated facility,” Interpace Chief Development Officer Alidad Mireskandari said in a statement. “We look forward to adopting our partners’ technology into our clinical operations to drive productivity and reduce costs as the value of their technology solutions become more evident in our validation work.”